Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019003148) MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

What is claimed is:

1. A compound of Formula I


Formula I

or a pharmaceutically acceptable salt thereof wherein:

each X is CH or one X is N and the other 3 are CH;

Q1 is a bond (i.e. is absent), -C(0)C-, or -C(O)-;

Q2 is a bond (i.e. is absent) or -C(O)-;

R1 is absent, halogen, Ci-3alkylOH, or C(0)OCi-3alkyl;

R3 is C5-garyl, or 5-9 membered heteroaryl, wherein aryl and heteroaryl include bicycles and heteroaryl contains 1-3 hetero atoms selected from O, S, and N, and wherein R3 may optionally be substituted with a substituent selected from halogen, OH, Ci_3alkyl, OCi-3alkyl, Ci.3fluoroalkyl, CN, and NH2; and

R4 is H, Ci_3haloalkyl, phenyl or Ci-6alkyl

2. A compound or salt according to Claim 1 wherein each X is CH.

3. A compound or salt according to Claim 1 or Claim 2 wherein Q1 is C(0)0.

4. A compound or salt according to any of Claims 1-3 wherein Q2 is C(O).

5. A compound or salt according to any of Claims 1-4 wherein R1 is Br, OCH3, or is absent.

6. A compound or salt according to any of Claims 1 -5 wherein R3 is indole, benzodiazole, phenyl, pyridyl, diazole, or pyrimidine, and wherein R3 may optionally be substituted with a substituent selected from halogen, OH, Ci_3alkyl, OCi-3alkyl, Ci_ 3fluoroalkyl, CN, and NH2.

7. A compound or salt according to Claim 6 wherein R3 is indole or benzodiazole, and wherein R3 may optionally be substituted with a substituent selected from halogen, OH, Ci-3alkyl, OCi-3alkyl, Ci-3fluoroalkyl, CN, and NH2.

8. A compound or salt according to Claim 7 wherein R3 is unsubstituted indazole.

9. A compound or salt according to any of Claims 1 -8 wherein R4 is H, Ci_4alkyl, CF3, or phenyl.

10. A compound or salt according to Claim 9 wherein R4 is Ci_ alkyl.

11 . A compound or salt according to Claim 1 wherein each X is CH; Q1 is C(0)0; Q2 is C(O); R1 is Br, OCH3, or is absent; R3 is indole, benzodiazole, phenyl, pyridyl, diazole, or pyrimidine, and wherein R3 may optionally be substituted with a substituent selected from halogen, OH, Ci_3alkyl, OCi-3alkyl, Ci-3fluoroalkyl, CN, and NH2; and R4 is H, d-4alkyl, CF3, or phenyl.

12. A pharmaceutical composition comprising a compound or salt according to any of Claims 1 -11 .

13. A method of treating a disease or condition that would benefit from inhibition of ID01 comprising the step of administration of a composition according to Claim 12.

14. The method of Claim 13 wherein in said disease or condition, biomarkers of IDO

activity are elevated.

15. The method of Claim 13 wherein said biomarkers are plasma kynurenine or the plasma kynurenine/ tryptophan ratio.

16. The method of Claim 13 wherein said disease or condition is chronic viral infection; chronic bacterial infections; cancer; sepsis; or a neurological disorder.

17. The method of Claim 13 wherein said chronic viral infections are those involving HIV, HBV, or HCV; said chronic bacterial infections are tuberculosis or prosthetic joint infection; and said neurological disorders are major depressive disorder, Huntington's disease, or Parkinson's disease.

18. The method of Claim 17 wherein said disease or condition is inflammation associated with HIV infection; chronic viral infections involving hepatitis B virus or hepatitis

C virus; cancer; or sepsis.

19. A compound or salt according to any of Claims 1 -11 for use in treating a disease or condition that would benefit from inhibition of ID01 .

20. Use of a compound or salt according to any of Claims 1 -11 in the manufacture of a medicament for treating a disease or condition that would benefit from inhibition of ID01 .